Vaxart, Inc. (VXRT)
OTCMKTS · Delayed Price · Currency is USD
0.3600
-0.0100 (-2.70%)
Aug 28, 2025, 3:59 PM EDT
Vaxart Revenue
Vaxart had revenue of $39.73M in the quarter ending June 30, 2025, with 520.68% growth. This brings the company's revenue in the last twelve months to $80.72M, up 479.58% year-over-year. In the year 2024, Vaxart had annual revenue of $28.70M with 288.94% growth.
Revenue (ttm)
80.72M
Revenue Growth
+479.58%
P/S Ratio
1.10
Revenue / Employee
768.80K
Employees
105
Market Cap
89.08M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.70M | 21.32M | 288.94% |
Dec 31, 2023 | 7.38M | 7.27M | 6,796.26% |
Dec 31, 2022 | 107.00K | -785.00K | -88.00% |
Dec 31, 2021 | 892.00K | -3.15M | -77.95% |
Dec 31, 2020 | 4.05M | -5.82M | -58.97% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 105.45M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
Vaxart News
- 8 days ago - Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights - GlobeNewsWire
- 15 days ago - Vaxart outlines accelerated COVID-19 trial data timeline and plans norovirus Phase IIb pending funding - Seeking Alpha
- 15 days ago - Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - US orders Vaxart to stop COVID-19 trial amid mRNA wind down - Reuters
- 16 days ago - Vaxart Revenue Jumps 520% in Fiscal Q2 - The Motley Fool
- 17 days ago - Vaxart's Earnings: A Preview - Benzinga
- 5 weeks ago - Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq - GlobeNewsWire
- 2 months ago - Vaxart Announces Preliminary Results of Annual Meeting of Stockholders - GlobeNewsWire